Investigation into the efficacy of three combination therapies compared with standard chemotherapy

CLL 13

Coordinating investigator

Dr. med.
Luzerner Kantonsspital
+41 41 205 53 13

Chronic lymphocytic leukaemia (CLL) is a form of leukaemia that usually progresses very slowly. The majority of those affected develop the condition between the ages of 65 and 75. CLL is the most common type of leukaemia in adults in the western world.

Patients with chronic lymphocytic leukaemia who are physically fit can take part in this clinical trial. We are investigating whether treatment with combined medications without standard chemotherapy is more effective and produces fewer side-effects than standard chemotherapy treatment.

We hope that patients treated with venetoclax and rituximab or obinutuzumab, possibly also combined with ibrutinib, will respond better to the therapy and have a longer disease-free period. All of the medicines used in the trial are authorized in either the USA or the EU for the treatment of CLL, although not all of them as a first-line therapy or not in the combinations used in the trial.

All trials